A Phase 2A Randomized, Placebo Controlled, Double Blind Study of the Protective Effects of EPI-743 (Vincerinone) on Noise-Induced Hearing Loss
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2018
Price : $35 *
At a glance
- Drugs Vatiquinone (Primary)
- Indications Noise-induced hearing loss
- Focus Therapeutic Use
- Sponsors BioElectronics Corporation; Edison Pharmaceuticals
- 18 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jan 2016 Planned End Date changed from 1 Sep 2015 to 1 Feb 2016, according to ClinicalTrials.gov record.
- 19 Jan 2016 Planned primary completion date changed from 1 Jul 2015 to 1 Nov 2015, according to ClinicalTrials.gov record.